Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theaphenon 95
- Development stage
- Phase 2
- Lead developer
- LSU Health Sciences Center New Orleans
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Theaphenon 95 is a highly purified green tea extract containing 95% epigallocatechin-gallate (EGCG), a polyphenol compound with potent antioxidant and anti-inflammatory properties. It was investigated by the Louisiana State University Health Sciences Center in New Orleans as a potential neuroprotective add-on therapy for patients with relapsing-remitting or secondary progressive multiple sclerosis (MS). The drug's mechanism of action is thought to involve the protection of brain cells from oxidative stress and the modulation of inflammatory pathways, potentially preserving neuronal integrity as measured by chemical markers like N-Acetyl-Aspartate (NAA). A Phase 2 clinical trial (NCT02011451) was initiated to evaluate its safety and neuroprotective effects at a total daily dose of 800mg, but the study was subsequently withdrawn before completion.
- Brand names
- Theaphenon 95Theaphenon95Theaphenon-95
- Other names
- Theaphenon 95%95% Pure EGCGepigallocatechin-gallateEGCG
02
Targets
NF-κBMMP9 (Matrix metalloproteinase-9)26S proteasome
Beyond the preview
Go deeper on Theaphenon 95.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theaphenon 95.